Mount Sinai West — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$8,550	8
2024	Research	$1,615	1
2023	Research	$791	1
2020	Research	$2,083	1
2019	Research	$97,322	7

Breakdown

Who paid Research payments · program years 2019–2025

Bausch Health US, LLC $94,032 5 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
E.R. Squibb & Sons, L.L.C. $3,768 3 payments
Seattle Genetics, Inc. $3,290 2 payments
Celgene Corporation $2,083 1 payment
Boehringer Ingelheim International GmbH $511 6 payments

Studies the money was for Research payments · program years 2019–2025

Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study $94,032 5 payments
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% $7,188 7 payments
An Open Label Phase 2 Study of Denintuzumab Mafodotin SGN-CD19A in Combination With RCHOP Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone or RCHP Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma DLBCL or Follicular Lymphoma FL Grade 3b $3,290 2 payments
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma $2,083 1 payment
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM) $1,615 1 payment
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy $1,362 1 payment
nHCM Phase III - A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy $791 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.